Randomized Controlled Trial of Infliximab (Remicade) Induction Therapy for Deceased Donor Kidney Transplant Recipients (CTOT-19)

Trial Profile

Randomized Controlled Trial of Infliximab (Remicade) Induction Therapy for Deceased Donor Kidney Transplant Recipients (CTOT-19)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Infliximab (Primary) ; Antithymocyte globulin; Diphenhydramine; Loratadine; Methylprednisolone; Mycophenolate mofetil; Paracetamol; Prednisone; Tacrolimus
  • Indications Inflammation
  • Focus Therapeutic Use
  • Acronyms CTOT-19
  • Most Recent Events

    • 12 Feb 2016 Planned End Date changed from 1 Aug 2020 to 1 Sep 2020, according to ClinicalTrials.gov record.
    • 12 Feb 2016 Planned primary completion date changed from 1 Aug 2020 to 1 Sep 2020, according to ClinicalTrials.gov record.
    • 07 Dec 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top